Elafibranor, a dual agonist for PPARα and PPARδ, has shown improved effectiveness in treating NASH compared to a placebo without negatively impacting fibrosis progression (107) (Figure 2). The gene discussed is PPARD; the disease is metabolic dysfunction-associated steatohepatitis.